HUTCHMED (China) Ltd
LSE:HCM
Intrinsic Value
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. [ Read More ]
The intrinsic value of one
HCM
stock under the Base Case scenario is
257.96
GBX.
Compared to the current market price of 304 GBX,
HUTCHMED (China) Ltd
is
Overvalued by 15%.
HUTCHMED (China) Ltd's market capitalization is 2.6B GBX.
HCM stock price is 304 GBX.
HCM stock (257.96 GBX) is 15% less than its price (304 GBX).
HCM has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
HCM's Altman Z-Score is equal to 2.58.
HCM's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
HCM's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 5%.
HCM's Revenue is forecast to grow at a rate of 9% per year over the next 3 years.
HCM has positive Gross Profit for the last twelve months.
HCM's Revenue has grown by an exceptional 97% over the past 12 months.
HCM's ROE (Return on Equity) has significantly increased in the last 3 years from -33% to 14%.
HCM's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -85% to 5%.
HCM has positive Operating Income for the last twelve months.
HCM has positive Net Income for the last twelve months.
HCM's long-term assets (1B USD) exceed its long-term liabilties (515m USD).
HCM's Revenue has been growing by an exceptional 54% per year for the last 3 years.
HCM has positive Free Cash Flow for the last twelve months.
HCM's short-term assets (1B USD) exceed its short-term liabilties (341m USD).
HCM's D/E (Debt to Equity) is very low and is equal to 0.05.
HCM has negative three-year average ROE (Return on Equity): -21%. The company is not efficient at transforming stockholders' equity into net income.
HCM has negative three-year average ROIC (Return on Invested Capital): -80%. The company is not efficient at using invested capital to generate operating income.
HCM has negative Net Debt. This means that the company has more cash and short-term investments (857m USD) than debt (40m USD).
HCM earns more than enough operating income (18m USD) to safely cover interest payments on its debt (421k USD).
Valuation Backtest
HUTCHMED (China) Ltd
Run backtest to discover the historical profit from buying and selling
HCM
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
HUTCHMED (China) Ltd
Balance Sheet Decomposition
HUTCHMED (China) Ltd
| Current Assets | 1.1B |
| Cash & Short-Term Investments | 857.4m |
| Receivables | 167.2m |
| Other Current Assets | 65.9m |
| Non-Current Assets | 207m |
| Long-Term Investments | 37.7m |
| PP&E | 96.8m |
| Other Non-Current Assets | 72.4m |
| Current Liabilities | 340.9m |
| Accounts Payable | 54.6m |
| Accrued Liabilities | 213.4m |
| Other Current Liabilities | 72.9m |
| Non-Current Liabilities | 174.6m |
| Long-Term Debt | 40.1m |
| Other Non-Current Liabilities | 134.4m |
Earnings Waterfall
HUTCHMED (China) Ltd
|
Revenue
|
838m
USD
|
|
Cost of Revenue
|
-384.4m
USD
|
|
Gross Profit
|
453.6m
USD
|
|
Operating Expenses
|
-435.2m
USD
|
|
Operating Income
|
18.4m
USD
|
|
Other Expenses
|
82.4m
USD
|
|
Net Income
|
100.8m
USD
|
Free Cash Flow Analysis
HUTCHMED (China) Ltd
HCM Profitability Score
Profitability Due Diligence
HUTCHMED (China) Ltd's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
HUTCHMED (China) Ltd's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
HCM Solvency Score
Solvency Due Diligence
HUTCHMED (China) Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
HUTCHMED (China) Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HCM Price Targets Summary
HUTCHMED (China) Ltd
According to Wall Street analysts, the average 1-year price target for
HCM
is 386.56 GBX
with a low forecast of 274.22 GBX and a high forecast of 483 GBX.
Shareholder Return
HCM Price
HUTCHMED (China) Ltd
| Average Annual Return | -7.89% |
| Standard Deviation of Annual Returns | 28.87% |
| Max Drawdown | -78% |
| Market Capitalization | 2.6B GBX |
| Shares Outstanding | 853 644 032 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
HUTCHMED (China) Ltd
Country
Industry
Market Cap
Dividend Yield
Description
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Contact
IPO
Employees
Officers
The intrinsic value of one
HCM
stock under the Base Case scenario is
257.96
GBX.
Compared to the current market price of 304 GBX,
HUTCHMED (China) Ltd
is
Overvalued by 15%.
You don't have any saved screeners yet
